Harwig Alex, Kruize Zita, Yang Zhenhuang, Restle Tobias, Berkhout Ben
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Institute of Molecular Medicine, Universitätsklinikum Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
PLoS One. 2017 Aug 15;12(8):e0183269. doi: 10.1371/journal.pone.0183269. eCollection 2017.
The RNA interference (RNAi) pathway was recently expanded by the discovery of multiple alternative pathways for processing of natural microRNA (miRNA) and man-made short hairpin RNA (shRNA) molecules. One non-canonical pathway bypasses Dicer cleavage and requires instead processing by Argonaute2 (Ago2), which also executes the subsequent silencing step. We named these molecules AgoshRNA, which generate only a single active RNA strand and thus avoid off-target effects that can be induced by the passenger strand of a regular shRNA. Previously, we characterized AgoshRNA processing by deep sequencing and demonstrated that-after Ago2 cleavage-AgoshRNAs acquire a short 3' tail of 1-3 A-nucleotides and are subsequently trimmed, likely by the poly(A)-specific ribonuclease (PARN). As a result, the mature single-stranded AgoshRNA may dock more stably into Ago2. Here we set out to analyze the activity of different synthetic AgoshRNA processing intermediates. Ago2 was found to bind preferentially to partially single-stranded AgoshRNA in vitro. In contrast, only the double-stranded AgoshRNA precursor associated with Ago2 in cells, correlating with efficient intracellular processing and reporter knockdown activity. These results suggest the presence of a cellular co-factor involved in AgoshRNA loading into Ago2 in vivo. We also demonstrate specific AgoshRNA loading in Ago2, but not Ago1/3/4, thus further reducing unwanted side effects.
最近,随着天然微小RNA(miRNA)和人工短发夹RNA(shRNA)分子加工的多种替代途径的发现,RNA干扰(RNAi)途径得到了扩展。一种非经典途径绕过了Dicer切割,而是需要由Argonaute2(Ago2)进行加工,Ago2也执行随后的沉默步骤。我们将这些分子命名为AgoshRNA,它们只产生一条活性RNA链,因此避免了常规shRNA的过客链可能诱导的脱靶效应。此前,我们通过深度测序对AgoshRNA加工进行了表征,并证明在Ago2切割后,AgoshRNAs获得了1-3个A核苷酸的短3'尾巴,随后可能被聚(A)特异性核糖核酸酶(PARN)修剪。结果,成熟的单链AgoshRNA可能更稳定地对接入Ago2。在这里,我们着手分析不同合成AgoshRNA加工中间体的活性。发现Ago2在体外优先结合部分单链AgoshRNA。相反,只有双链AgoshRNA前体在细胞中与Ago2相关联,这与有效的细胞内加工和报告基因敲低活性相关。这些结果表明存在一种细胞辅因子参与体内AgoshRNA加载到Ago2中。我们还证明了AgoshRNA在Ago2中特异性加载,而不在Ago1/3/4中加载,从而进一步减少了不必要的副作用。